Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of Shattuck Labs, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001680367.
Disclosed value leader
T. Rowe Price Investment Management, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- STTK on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001680367
- Issuer location
- Austin, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Shattuck Labs, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
T. Rowe Price Investment ...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
14%
ORBIMED ADVISORS LLC
10%
Redmile Group, LLC
9.9%
Prosight Management, LP
9.9%
ADAGE CAPITAL PARTNERS GP, L.L.C.
9.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
14%
from 13D/G
|
$63,436,000
9,865,558 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
13F
Director · Company
|
10%
|
$58,005,847
9,021,127 shares
|
+$17,457,450 | 11 Jun 2026 |
| Redmile Group, LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
9.9%
|
$63,136,710
9,819,084 shares
|
+$22,119,129 | 09 Jun 2026 |
| Prosight Management, LP |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$32,178,543
5,004,439 shares
|
— | 31 Mar 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
13D/G
Company · Adage Capital Management, L.P.
|
9.8%
from 13D/G
|
$29,867,074
4,644,957 shares
|
— | 31 Mar 2026 |
| Deep Track Capital, LP |
13D/G
|
5.2%
|
$30,450,201
5,000,033 shares
|
$0 | 10 Jun 2026 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.5%
|
$1,437,343
2,148,174 shares
|
$0 | 30 Jun 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
1.8%
from 13D/G
|
$3,284,483
510,806 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$10,601,803.
Buys
$11,193,653
Insiders: 3
Sells
$591,850
Insiders: 2
Net
+$10,601,803
Shares: +12,588,847
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 12,674,754
Shares: 85,907
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 62,500 | 85,907 | $250,000 | $591,850 | -$341,850 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 12,612,254 | 0 | $10,943,653 | $0 | +$10,943,653 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to Shattuck Labs, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Josiah Hornblower
Net 12M change
+$10,601,802
Latest report
02 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Josiah Hornblower | Director | $33,436,202 | Mixed | 15 Jul 2021 | ||
| Taylor Schreiber | Chief Executive Officer, Director | $17,573,009 | Mixed | 12 May 2026 | ||
| Redmile Group, LLC | Director, 10%+ Owner | $6,924,655 | Mixed | 25 Aug 2025 | ||
| OrbiMed Genesis GP LLC | Director | $6,758,065 | Mixed | 11 Jun 2026 | ||
| Mona Ashiya | Director | $6,758,065 | +$5,471,826 | +425% | Mixed | 11 Jun 2026 |
| ORBIMED ADVISORS LLC | Director | $6,758,065 | +$5,471,826 | +425% | Mixed | 11 Jun 2026 |
| OrbiMed Capital GP IX LLC | Director | $6,758,065 | Mixed | 11 Jun 2026 | ||
| Andrew R. Neill | Chief Financial Officer | $1,879,173 | Mixed | 12 May 2026 | ||
| Clay B. Siegall | Director | $1,274,432 | +$250,000 | +24% | Filing P/S | 09 Jun 2026 |
| Erin Ator Thomson | General Counsel | $1,041,379 | Mixed | 25 Jan 2023 | ||
| Arundathy N. Pandite | Chief Medical Officer | $954,895 | -$408,600 | -30% | Filing P/S | 30 Jun 2026 |
| Abhinav A. Shukla | Chief Technical Officer | $633,567 | -$183,250 | -22% | Mixed | 02 Jul 2026 |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer | $600,343 | Mixed | 15 May 2026 | ||
| Casi DeYoung | Chief Business Officer | $304,942 | Mixed | 25 Jan 2026 | ||
| Helen M. Boudreau | Director | Mixed | 29 May 2026 | |||
| Neil W. Gibson | Director | Mixed | 29 May 2026 | |||
| Carrie Brownstein | Director | Mixed | 14 Jul 2025 | |||
| Tyler Brous | Director | Mixed | 14 Jul 2025 | |||
| George Golumbeski | Director | Mixed | 29 May 2026 | |||
| Dr. Daniel G. Baker | Director | Mixed | 29 May 2026 |
Recent insider transactions for Shattuck Labs, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Abhinav A. Shukla | STTK | Common Stock | Options Exercise | 14.1% | 12,153 | 98,533 | 06 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Stock Option (Right to Buy) | Options Exercise | -46.2% | -12,153 | 14,140 | 06 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Common Stock | Sale | -0.47% | $2,874 | $7.01 | -410 | 86,380 | 02 Jul 2026 | Direct |
| Abhinav A. Shukla | STTK | Common Stock | Options Exercise | 0.47% | 410 | 86,790 | 02 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Stock Option (Right to Buy) | Options Exercise | -1.54% | -410 | 26,293 | 02 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Common Stock | Sale | -0.12% | $707 | $7.07 | -100 | 86,380 | 01 Jul 2026 | Direct |
| Abhinav A. Shukla | STTK | Common Stock | Options Exercise | 0.12% | 100 | 86,480 | 01 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Stock Option (Right to Buy) | Options Exercise | -0.37% | -100 | 26,703 | 01 Jul 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Common Stock | Sale | -21.3% | $165,424 | $7.08 | -23,365 | 86,380 | 30 Jun 2026 | Direct |
| Abhinav A. Shukla | STTK | Common Stock | Options Exercise | 27% | 23,365 | 109,745 | 30 Jun 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Stock Option (Right to Buy) | Options Exercise | -46.6% | -23,365 | 26,803 | 30 Jun 2026 | Direct | ||
| Arundathy N. Pandite | STTK | Common Stock | Sale | -18% | $210,300 | $7.01 | -30,000 | 136,219 | 30 Jun 2026 | Direct |
| Mona Ashiya | STTK | Pre-Funded Warrants (right to buy) | Purchase | 4.95% | 1,250,000 | 26,519,541 | 11 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Purchase | 4.95% | 1,250,000 | 26,519,541 | 11 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Purchase | 4.95% | 1,250,000 | 26,519,541 | 11 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Purchase | 4.95% | 1,250,000 | 26,519,541 | 11 Jun 2026 | See Footnote | ||
| Clay B. Siegall | STTK | Common Stock | Purchase | 24.4% | $250,000 | $4.00 | 62,500 | 318,608 | 09 Jun 2026 | Direct |
| Orbimed Advisors Llc | STTK | Common Warrants (right to buy) | Conversion of derivative security | -100% | -18,439,788 | 0 | 08 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Common Warrants (right to buy) | Conversion of derivative security | -100% | -18,439,788 | 0 | 08 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Common Warrants (right to buy) | Conversion of derivative security | -100% | -18,439,788 | 0 | 08 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Conversion of derivative security | 262% | 18,439,788 | 25,477,874 | 08 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Conversion of derivative security | 262% | 18,439,788 | 25,477,874 | 08 Jun 2026 | See Footnote | ||
| Orbimed Advisors Llc | STTK | Pre-Funded Warrants (right to buy) | Conversion of derivative security | 262% | 18,439,788 | 25,477,874 | 08 Jun 2026 | See Footnote | ||
| Mona Ashiya | STTK | Common Warrants (right to buy) | Conversion of derivative security | -100% | -18,439,788 | 0 | 08 Jun 2026 | See Footnote | ||
| Mona Ashiya | STTK | Pre-Funded Warrants (right to buy) | Conversion of derivative security | 262% | 18,439,788 | 25,477,874 | 08 Jun 2026 | See Footnote | ||
| Dr. Daniel G. Baker | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| George Golumbeski | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| Neil W. Gibson | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| Dr. Mona Ashiya | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| Clay B. Siegall | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| Helen M. Boudreau | STTK | Stock Option (Right to Buy) | Award | 81,000 | 81,000 | 29 May 2026 | Direct | |||
| Clay B. Siegall | STTK | Common Stock | Award | 100% | 128,054 | 256,108 | 22 May 2026 | Direct | ||
| Clay B. Siegall | STTK | Warrants (Right to Buy) | Options Exercise | -100% | -128,054 | 0 | 22 May 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Common Stock | Award | 6.3% | 5,122 | 86,380 | 21 May 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Warrants (Right to Buy) | Options Exercise | -100% | -5,122 | 0 | 21 May 2026 | Direct | ||
| Stephen Stout | STTK | Common Stock | Award | 15.9% | 12,805 | 93,366 | 15 May 2026 | Direct | ||
| Stephen Stout | STTK | Warrants (Right to Buy) | Options Exercise | -100% | -12,805 | 0 | 15 May 2026 | Direct | ||
| Andrew R. Neill | STTK | Common Stock | Award | 28% | 64,027 | 292,251 | 12 May 2026 | Direct | ||
| Andrew R. Neill | STTK | Warrants (Right to Buy) | Options Exercise | -100% | -64,027 | 0 | 12 May 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Common Stock | Sale | -2.44% | $14,244 | $7.01 | -2,032 | 81,258 | 12 May 2026 | Direct |
| Abhinav A. Shukla | STTK | Common Stock | Options Exercise | 2.5% | 2,032 | 83,290 | 12 May 2026 | Direct | ||
| Abhinav A. Shukla | STTK | Stock Option (Right to Buy) | Options Exercise | -3.89% | -2,032 | 50,168 | 12 May 2026 | Direct | ||
| Arundathy N. Pandite | STTK | Common Stock | Sale | -15.3% | $198,300 | $6.61 | -30,000 | 166,219 | 12 May 2026 | Direct |
| Taylor Schreiber | STTK | Common Stock | Award | 26.5% | 25,610 | 122,222 | 12 May 2026 | Direct | ||
| Taylor Schreiber | STTK | Warrants (Right to Buy) | Options Exercise | -100% | -25,610 | 0 | 12 May 2026 | Direct | ||
| Stephen Stout | STTK | Common Stock | Tax liability | -1.19% | -968 | 80,561 | 10 May 2026 | Direct | ||
| Arundathy N. Pandite | STTK | Common Stock | Tax liability | -1.6% | -3,195 | 196,219 | 25 Jan 2026 | Direct | ||
| Stephen Stout | STTK | Common Stock | Tax liability | -0.72% | -593 | 81,529 | 25 Jan 2026 | Direct | ||
| Andrew R. Neill | STTK | Common Stock | Tax liability | -1.12% | -2,589 | 228,224 | 25 Jan 2026 | Direct | ||
| Casi DeYoung | STTK | Common Stock | Tax liability | -3.02% | -2,286 | 73,480 | 25 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.